Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/10/2022* -- Results Q3 2022 -- -0.16 --
11/10/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
07/25/2022 16:30 EST Earnings Call Q2 2022 -- -- --
07/25/2022 -- Results Q2 2022 -0.17 -0.17 2.41%
05/09/2022 -- Results Q1 2022 -0.20 -0.20 -2.56%
05/09/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/28/2022 -- Results Q4 2021 -0.20 -0.18 -14.29%
02/28/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/10/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/25/2022
Beat/Miss Upgrade
Return Since -85.83%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
URL https://www.otonomy.com
Investor Relations URL http://investors.otonomy.com/phoenix.zhtml?c=234082&p=irol-irhome
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 10, 2022 (est.)
Last Earnings Release Jul. 25, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-16.74%
-42.70%
-65.09%
-66.67%
107.0%
68.93%
-67.85%
-86.71%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.61%
--
--
--
--
--
--
--
-86.51%
-48.57%
-13.89%
-19.35%
-52.00%
-100.00%
-71.83%
7.10%
-68.23%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-70.79%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-50.12%
As of September 23, 2022.

Profile

Edit
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
URL https://www.otonomy.com
Investor Relations URL http://investors.otonomy.com/phoenix.zhtml?c=234082&p=irol-irhome
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 10, 2022 (est.)
Last Earnings Release Jul. 25, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter OTIC Tweets